-+ 0.00%
-+ 0.00%
-+ 0.00%
Lantern Pharma Q2 FY26 operating loss narrows 25% to $3.5 million; net loss widens to $7.1 million
Share
Listen to the news
Lantern Pharma Q2 FY26 operating loss narrows 25% to $3.5 million; net loss widens to $7.1 million
  • Lantern Pharma posted a Q2 2026 net loss of USD 7.1 million, or USD 0.57 per share, widening from USD 4.3 million.
  • Operating loss narrowed 25% year over year to about USD 3.5 million, while cash and marketable securities totaled about USD 7.4 million.
  • R&D expense fell 42% to about USD 1.8 million; G&A expense rose 8% to about USD 1.7 million.
  • Warrant expense totaled about USD 3.6 million, driven mainly by a higher fair value tied to a stock-price increase.
  • Lantern formed Open Medicine AI as a separate company; LP-300 HARMONIC data showed 8.9-month median PFS in L858R patients completing six cycles.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608140730BIZWIRE_USPR_____20260814_BW100282) on August 14, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending